Technical operations
![](/sites/default/files/annual-reports/modifs-pour-images-19.jpg)
Biologic drugs are derived from living cells and their development requires a high level of expertise. Because the physical and chemical properties of biopharmaceutical material can affect the quality and stability attributes of a product, characterisation is critical throughout development and manufacturing. To ensure the quality and purity of our treatments, we use leading edge technologies, carry out stringent controls and apply hundreds of process controls to ensure that quality attributes are delivered.”
HAFIDA ELMIR
Stallergenes Greer is ramping up its Technical Operations to meet the evolving needs of the pharmaceutical industry, anticipate future demand and continuously ensure the efficient delivery of its allergen immunotherapy treatments to patients.
Supply chain resilience
Securing our supply chain remains a strategic imperative for the Group. We continuously strengthen the visibility, reliability, flexibility and efficiency of our supply chain to ensure uninterrupted product availability for the people who depend on them. Thanks to planning and visibility, our teams can anticipate fluctuations and manage our production capacity to ensure that our treatments remain available.
![](/sites/default/files/annual-reports/modifs-pour-images-20-2.jpg)
Innovation in motion
Each year, Stallergenes Greer invests significant amounts in its industrial tool to adapt to the latest regulatory standards and meet increasing market demand for the Group’s AIT treatments.
In line with this strategy, in 2023, the Group internalised the production of its AIT tablets at its Antony (France) site to anticipate demand; the first batches have already been released for France. A new flexible aseptic filling line is also being implemented in Antony and will be operational in 2025.
Operational efficiency to deliver value for our patients
Because our AIT treatments cater to the specific needs of patients, we continuously train our people in areas such as quality assurance, quality control, product development, and regulatory, and ensure they obtain certifications in key areas.
Stallergenes Greer is committed to safeguarding, and building on, its legacy expertise in AIT while constantly upgrading its industrial practices and processes to prepare the future.
![](/sites/default/files/annual-reports/modifs-pour-images-20-3.jpg)
My birch allergy symptoms were so severe that I frequently missed school. And when spring came, while my friends were outdoors, I couldn’t wait for the rain to fall!”
CORPORATE RESPONSIBILITY FACTS ECO-DESIGNED PACKAGING
Our new fully automated, connected and flexible packaging line in Antony (France) is capable of producing packaging with a significant level of personalisation, at high speed. It easily adjusts to local pharmaceutical regulations while ensuring both the reliability of our packaging processes and the ability to meet future demand. It can evolve over time in line with the Group’s projects, such as providing the possibility to eco-design packaging, which is one of the Stallergenes Greer’s strategic commitments in terms of corporate responsibility.